Raymond James reiterates Strong Buy on Tyra Biosciences stock
Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.
How this was made
The 30-second read
Why it matters
The data suggests a strong market reaction potential, supporting a bullish stance.
Market read
New trial data could drive TYRA stock higher and influence biotech sector sentiment.
What to watch
Potential dilution from recent capital raise and competition from other FGFR3 inhibitors.
Background
Analyst coverage reiteration and fresh Phase 2 trial data for TYRA's lead asset dabogratinib in bladder cancer.
Ticker impact
Raymond James reiterated a Strong Buy and highlighted new Phase 2 data for dabogratinib with 79% overall response and 64% complete response rates.
upside pressure as the market absorbs the strong trial outcomes
Phase 2 data is a primary disclosure for a clinical-stage biotech; such data historically drives share price gains.
Market effects
Boosts sentiment for the broader biotech and oncology trial space.
May lift US biotech ETFs and related small-cap indices.
Highlights continued pipeline momentum in cancer therapeutics worldwide.
Counterpoint
If Phase 3 fails to confirm Phase 2 efficacy, the current optimism could reverse sharply.
Key entities
- companyTyra Biosciences
Clinical-stage biotech developing dabogratinib.
- analyst_firmRaymond James
Reiterated Strong Buy rating and $50 price target.
